1. Home
  2. CAPR vs CYD Comparison

CAPR vs CYD Comparison

Compare CAPR & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$35.29

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo China Yuchai International Limited

CYD

China Yuchai International Limited

HOLD

Current Price

$44.15

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
CYD
Founded
2005
1951
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2011
1998

Fundamental Metrics

Financial Performance
Metric
CAPR
CYD
Price
$35.29
$44.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
1
Target Price
$44.63
$60.00
AVG Volume (30 Days)
1.0M
104.6K
Earning Date
05-12-2026
02-24-2026
Dividend Yield
N/A
1.20%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$15.11
Revenue Next Year
$3.31
$8.67
P/E Ratio
N/A
$32.71
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$14.31
52 Week High
$40.37
$56.55

Technical Indicators

Market Signals
Indicator
CAPR
CYD
Relative Strength Index (RSI) 65.11 57.93
Support Level $22.09 $35.24
Resistance Level $36.49 $45.94
Average True Range (ATR) 2.10 1.93
MACD 0.21 0.59
Stochastic Oscillator 79.14 71.59

Price Performance

Historical Comparison
CAPR
CYD

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

Share on Social Networks: